Document is current
Any future updates will be listed below
-
Authors
Rodriguez, George D.
Warren, Nathan
Yashayev, Roman
Chitra, Surya
Amodio-Groton, Maria
Wright, Kelly https://orcid.org/0000-0003-2908-2612
-
Funding
Funding for this research was provided by:
Paratek
- License Information
-
More Information
Article History
Received: 26 April 2024
Accepted: 16 September 2024
First Online: 26 October 2024
Declarations
:
: Nathan Warren and Surya Chitra are Consultants for Paratek Pharmaceuticals, Inc. George D. Rodriguez has received travel support to present a poster version of this manuscript. Roman Yashayev declares that he has no competing interests. Maria Amodio-Groton and Kelly Wright are employees and shareholders of Paratek Pharmaceuticals, Inc.
: The OASIS-1 (ClinicalTrials.gov identifier NCT02378480) and OASIS-2 (ClinicalTrials.gov identifier NCT02877927) trials included in this post hoc analysis were conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki of 1964, and its later amendments. They were approved by the Institutional Review Board (IRB) or Ethics Committee (EC) at each participating site (Supplementary Table S3); the IRB/EC at each participating site approved the protocol and amendments. Each patient provided written informed consent prior to study participation.
